On Tuesday 22 February I delivered this presentation at the Q1 2nd Annual European Medical Devices Reimbursement Conference.

My presentation addressed the question of what constraints there are on companies providing information with respect to coverage and reimbursement to customers. There are many, both contained in mandatory law and self-regulatory rules.

It was remarkable to hear how similar and at the same time different national reimbursement systems are in the EU, as for medical devices no harmonisation has taken place yet in the field of reimbursement. For pharmaceuticals there is some in the form of the Transparency Directive. However, the upcoming Cross-Border Healthcare Directive is expected to lead to de facto harmonisation in the field of medical devices as it provides for a legal basis for HTA cooperation, as you will also see explained in brief in my presentation.